Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, describes how IDH inhibitors have significantly acute myeloid leukemia (AML) therapy. Dr Perl discusses how these treatments have increased survival rates in AML patients who have previously been unresponsive to therapy and those who were not candidates for intensive chemotherapy. He stresses the importance of personalized, precision medicines.
A success story: IDH inhibitors for AML
